DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
Key Highlights
- ➤DataMEDS terminates 2nd LOI with Datavault AI and other parties due to market conditions
- ➤DataMEDS will issue no shares related to the terminated 2nd LOI
- ➤DataMEDS owes no fees or obligations following the LOI termination
- ➤REBOOT exclusive GLP-1 management license remains in full force
- ➤Datavault PharmacyChain blockchain smart-contract agreement remains in full force
TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx(™) artificial intelligence platform and PharmacyChain(™) blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 ("2(nd) LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") and HealthBridge Advisors, LLC ("HealthBridge Advisors") for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination.
Get started
Create a free account to read the full story.